online casino 888
online casino 888
online casino 888
Arcadium Lithium Announces Shareholder Approval of Proposed Rio Tinto Transaction and Provides Regulatory Update
Unexpected ways AI is revolutionizing your daily tasks
Americans Have Little Sympathy for Murdered Health Insurance ExecWith rookie QB Penix showing poise in starting debut, the Falcons again control their playoff hopes
NoneChris Hipkins tells Labour NZ needs it to change – can it?
'I tried the Shark FlexStyle and it's a game-changer' — Save $75 ahead of Cyber MondayLabour pulls ahead of National in internal polling, as Hipkins plans tax pitch
2024’s top 10 climate disasters cost more than 200 billion dollars, charity says
More homeless Minnesotans live outside than a decade ago, Wilder Foundation findsUnlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle Griffin had no trouble getting them. The 38-year-old information technology worker from New Mexico had a prescription. Her pharmacy had the drugs in stock. And her health insurance covered all but $25 to $50 of the monthly cost. For Griffin, the hardest part of using the new drugs wasn’t access. It was finding out that the much-hyped medications didn’t really work for her. “I have been on Wegovy for a year and a half and have only lost 13 pounds,” said Griffin, who watches her diet, drinks plenty of water and exercises regularly. “I’ve done everything right with no success. It’s discouraging.” In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of their body weight. Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications. It's a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results. “It's all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Genetics, hormones and variability in how the brain regulates energy can all influence weight — and a person's response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives. “This is a disease that stems from the brain,” said Stanford. “The dysfunction may not be the same” from patient to patient. Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge. “It can be devastating,” said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and co-founder of the obesity treatment company FlyteHealth. “With such high expectations, there’s so much room for disappointment.” That was the case for Griffin, who has battled obesity since childhood and hoped to shed 70 pounds using Wegovy. The drug helped reduce her appetite and lowered her risk of diabetes, but she saw little change in weight. “It’s an emotional roller coaster,” she said. “You want it to work like it does for everybody else.” The medications are typically prescribed along with eating behavior and lifestyle changes. It’s usually clear within weeks whether someone will respond to the drugs, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Weight loss typically begins right away and continues as the dosage increases. For some patients, that just doesn't happen. For others, side effects such as nausea, vomiting and diarrhea force them to halt the medications, Dushay said. In such situations, patients who were counting on the new drugs to pare pounds may think they’re out of options. “I tell them: It's not game over,” Dushay said. Trying a different version of the new class of drugs may help. Griffin, who didn't respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost 7 pounds. “I'm hoping it's slow and steady,” she said. Other people respond well to older drugs, the experts said. Changing diet, exercise, sleep and stress habits can also have profound effects. Figuring out what works typically requires a doctor trained to treat obesity, Saunders noted. “Obesity is such a complex disease that really needs to be treated very comprehensively,” she said. “If what we’re prescribing doesn’t work, we always have a backup plan.” The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Justin Herbert threw three touchdowns as the Los Angeles Chargers booked their place in the NFL playoffs with a blowout 40-7 win at the New England Patriots on Saturday. The Patriots, who suffered a sixth straight loss, were booed off the field by the remaining fans at Gillette Stadium as they fell to 3-13 on the season. But for the Chargers it was a job well done as the confident Herbert ensured a second post-season place in three seasons with another accomplished quarterback display. Herbert completed 28 of 38 passes and threw for 281 yards against a Patriots defense that caused few issues against the passing game. The Chargers took the lead late in the first quarter thanks to a beautiful 23-yard Herbert pass, superbly caught by the diving Derius Davis. After a Cameron Dicker field goal early in the second, Herbert found rookie receiver Ladd McConkey at the back of the end-zone with a pinpoint pass to make it 17-0. Patriots rookie quarterback Drake Maye had been forced out of the game in the first quarter after suffering a hit to the head by Cam Hart when running down the sideline. But Maye, who had been cleared to return for the second quarter, showed he was in good shape with a fine 36-yard touchdown pass to DeMario Douglas to give the Patriots some hope. But the Chargers ran away with the game with Herbert again connecting with McConkey, this time with a 40-yard pass down the middle and a two-yard rush from J.K Dobbins in the fourth completed the rout. Herbert's performance meant he set a new record for the most passing yards in the first five years of an NFL career -- passing Peyton Manning's tally of 20,618 yards. But the quarterback, who has yet to win a playoff game, was quick to give credit for his achievement to his team-mates. "It says so much about the guys we had catching those passes and a great offensive line giving me the time to get the ball off and (the defense) getting me the ball back," he said. "I couldn't have done it without them," he added. The Denver Broncos can clinch a place in the playoffs when they face the Bengals in Cincinnati later on Saturday. sev/nf
Wall Street's primary indexes closed on a high note Monday, with the Nasdaq and Dow Jones achieving a three-day winning streak. The gains were bolstered by influential tech stocks, especially on a day with reduced trading due to the holiday. Tech giants Meta Platforms, Nvidia, and Tesla exhibited significant increases, ranging from 2.3% to 3.7%. Their performance helped the Nasdaq and Dow Jones secure their consecutive wins, while the S&P 500 marked its second rise in three sessions. The rally follows a challenging period, notably after the U.S. Federal Reserve adjusted its rate cut predictions. Despite some volatility, trends in tech stocks remain strong, with a potential 'Santa Claus Rally' anticipated by market analysts as the year-end approaches. (With inputs from agencies.)Brock Bowers of the Las Vegas Raiders moved past Pro Football Hall of Famer Mike Ditka on Sunday to set the NFL record for most receiving yards by a tight end in his rookie season and also set the record for most receptions by a rookie, regardless of position. Bowers has 108 receptions to top the mark set last season by Puka Nacua (105) of the Los Angeles Rams. Bowers' yardage stands at 1,144 after having seven receptions for 77 yards in a 25-10 road victory over the New Orleans Saints. Bowers also set a franchise receptions for catches in a season, surpassing Darren Waller (107 in 2020). "It's awesome," Bowers said of the records in a postgame interview on Fox. "You never know what to expect coming up to the next level. It's been everything and more." Bowers' third catch on Sunday -- a 13-yard grab late in the second quarter against the Saints -- pushed his season total to 1,087 yards. Ditka totaled 1,076 receiving yards in 14 games with the Chicago Bears in 1961. Bowers, 22, set the record for receptions by a rookie tight end earlier this season by eclipsing the total of 86 reeled in by Sam LaPorta of the Detroit Lions in 2023. Bowers was selected by the Raiders with the 13th overall pick of the 2024 NFL Draft. Despite all his catches, he has just four scoring receptions. While with Georgia, Bowers was the first back-to-back winner of the Mackey Award (2022, 2023), which is given to the top tight end in college football. --Field Level Media
- nsjb
- jiliko 68
- jili games free bonus
- DC!lJuXlrz=:H(Ogs[Z/DpчMRS(P@&S "Я/¯s i?Ls o3s@Th,L6ÛVv!.e`vf{#Y [r5{@GQf{L>wӯGr[_,W\f@ݧ6KW! }?Y4gnPK X "ZR ( slot.txti wqP h'@
- what casino was casino royale filmed in
- 22bet live casino
- jili 333
- connections game
- how to earn money online game
- how to earn money online game
